## genzyme

Legal FAX

DATE: 4/22/04

TO: Examiner Karen Canella

COMPANY: USPTO

FAX: 703-872-9306

FROM: Elizabeth Lassen

E-MAIL: elizabeth.lassen@genzyme.com

PHONE: 508-270-2553

FAX: 508-872-5415

NO. OF PP (inc. cover): 20

### Dear Examiner Canella:

Further to your voicemail message, enclosed find the response to the September 10, 2003 non-final Office Action as filed on March 10, 2004. If you have any further questions, please do not he sitate to contact me.

RECEIVED CENTRAL FAX CENTER

APR 2 2 2004

OFFICIAL

Notice of confidentiality. This transmission is intended only for the use of the addressee(s) listed above and may contain information that is confidential and privileged. If you are not the intended recipient, an agent of the recipient, or an agent responsible for delivering it to the intended recipient, you are notified that you have received this document in error and any use, disclosure, copying or communication of the contents of this transmission is prohibited. If you have received this transmission in error, please telephone us immediately and return the message to us by mail.

Thank you

# HERTERFER IN THE WAS DAVIEND AND TRADENERAL OFFICE

## PLEASE ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

A Transmittal; Fee Transmittal (in duplicate); Response to non-final Office Action mailed September 10, 2003 from the USPTO (11 pages); Petition for Extension of Time (in duplicate); unexecuted Declaration and Power of Attorney (4 sheets) all including Certificates of First 6) 488

APPLICANT: ROB
APPLICATION NO: 09/82
FILING DATE: April

ROBERTS et al. 09/826,609 April 5, 2001

April 5, 2001
GENES DIFFERENTIALLY EXPRESSED IN CANCER CELLS TO DESIGN CANCER

VACCINES

03/10/04

**GA0150C** 

PAGE 2/20 \* RCVD AT 4/22/2004 2:36:55 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-1/0 \* DNIS:8729306 \* CSID:508 872 5415 \* DURATION (mm-ss):11-30

| Please type a plus sign (+) inside this box   |                  | U.S. Patent and Trademark                                 | d for use through 10/31/2002. OMB 0651-0031<br>Office: U.S. DEPARTMENT OF COMMERCE<br>hallon unless it displays a valid OMB control number.            |  |  |  |  |  |
|---|------------------|---|--|--|--|--|--|--|
| Under the Paperwork Reduced Pactor 1860, in   | porazino di Cir. | Application Number  | 09/826,609   |  |  |  |  |  |
| TRANSMITTAL   |                  | Filing Date   | April 5, 2001  |  |  |  |  |  |
| FORM  (to be used for all correspondence after initial filing)  Total Number of Pages In This Submission                    |                  | First Named Inventor                                      | ROBERTS et al.   |  |  |  |  |  |
|   |                  | Group Art Unit  |  |  |  |  |  |  |
|   |                  | Examiner Name   | Karen A. Canella   |  |  |  |  |  |
|   |                  | Attorney Docket Number                                    | GA0150C  |  |  |  |  |  |
| <u> </u>  |                  | OSURES (check all that apply)                             |  |  |  |  |  |  |
| Fee Transmittal Form (IN dup.)  | Assign           | ment Papers Application)                                  | After Allowance Communication to   |  |  |  |  |  |
| ( <i>IN du.f.</i> )<br>☐ Fee Attached   | ☐ Drawit         | ••  | Appeal Communication to Board of Appeals and Interferences   |  |  |  |  |  |
| Amendment / Response  | Licens           | sing-related Papers                                       | Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  |  |  |  |  |  |
| After Final   | Petitio          | n   | Proprietary Information  |  |  |  |  |  |
| Affidavits/declaration(s)   | ,                | n to Convert to a<br>sional Application                   | Status Letter  |  |  |  |  |  |
| Extension of Time Request   |                  | r of Attorney, Revocation<br>ge of Correspondence Address | Other Enclosure(\$) (please identify below):   |  |  |  |  |  |
| (iNdup.)   <sub>□ Termi</sub>   |                  | nal Disclaimer  | Unexecuted Declaration and   |  |  |  |  |  |
| Express Abandonment Request   | _                | est for Refund  | Power of Attorney Form (4 sheets): and return postcard   |  |  |  |  |  |
| Information Disclosure Statement  | ☐ CD, N          | lumber of CD(s)   |  |  |  |  |  |  |
| Certified Copy of Priority Document(s)  | Rem              | arks  |  |  |  |  |  |  |
| Response to Missing Parts/ Incomplete Application   |                  |   |  |  |  |  |  |  |
| Response to Missing<br>Parts under 37 CFR<br>1.52 or 1.53   |                  |   |  |  |  |  |  |  |
| SIGN  | ATURE OF         | APPLICANT, ATTORNEY, C                                    | OR AGENT   |  |  |  |  |  |
| Firm Genzyme Corporation or 15 Pleasant Street Connector Individual name P.O. Box 9322 Frapringham, Massachusetts 017979322 |                  |   |  |  |  |  |  |  |
| Signature Elijaluth Faon  |                  |   |  |  |  |  |  |  |
| Date Mark 10, 2004  |                  |   |  |  |  |  |  |  |
|   |                  | ERTIFICATE OF MAILING                                     |  |  |  |  |  |  |
| I hereby certify that this correspondence addressed to: Assistant Commissioner  |                  |   | tal Service as first class mail in an envelope ate: March 10, 2004   |  |  |  |  |  |
| Typed or printed name TABYN AN  |                  | 1   | <u> </u>   |  |  |  |  |  |
| Signature / Why wtalled Date 3-10-2004  |                  |   |  |  |  |  |  |  |
| comments on the amount of time you are rec  | ulred to comp    | lete this form should be send to the C                    | pending upon the needs of the individual case. An<br>thei information Officer, U.S. Patent and Trademar<br>ADDRESS. SEND TO: Assistant Commissioner fo |  |  |  |  |  |

PTO/SB/17 (10-03)
Approved for use through 07/31/2006, OMB 0651-0032
rademark Office; U.S. DEPARTMENT OF COMMERCE

| Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number. |   |   |                      |                  |   |                       |  |
|---|---|---|----------------------|------------------|---|-----------------------|--|
| FEE TRANSMITTAL   |   |   | Complete If Known    |                  |   |                       |  |
|   |   |   | Application Number   |                  | 09/826,609  |                       |  |
| for FY 2004   | Filing Date   |   |                      | April 5, 2001    |   |                       |  |
| <b>-</b>  | First Named Inventor                                      |   | ventor               | ROBERTS et al.   |   |                       |  |
| Effective 1010112003, Patent less are subject to annual revision.   | Examiner Name   |   | ie                   | Karen A. Canella |   |                       |  |
| Applicant claims small entity status. See 37 CFR 1.27   |   | Art Unit  |                      |                  | 1642  |                       |  |
| TOTAL AMOUNT OF PAYMENT (\$) 950.00   |   | Attorney Docket No.   |                      | et No.           | GA0150C   |                       |  |
| METHOD OF PAYMENT (check all that apply)  |   | FEE CALCULATION (continued)                                   |                      |                  |   |                       |  |
| Check Credit card Money Other None  | 3. ADDITIONAL FEES  |   |                      |                  |   |                       |  |
| Deposit Account:  |   | Large Entity Small Entity Fee Fee Fee Fee Fee Fee Pescrintion |                      |                  |   |                       |  |
| Deposit 074   |   | Fee<br>le (\$)  | Fea Fea<br>Code (\$) |                  | Fee Description   | Fee Pald              |  |
| Account 07-1074   | 105   | 1 130   | 2051                 |                  | harge - late filing fee or cath   |                       |  |
| Deposit GENZYME CORPORATION   |   | 2 50  | 2052                 |                  | harge - late provisional filing fee or<br>r sheel                       | <b>├</b> ──┤ <b>│</b> |  |
| Name  |   | 3 130   | 1063 1               | 30 Non-          | English specification   | <u> </u>              |  |
| The Director is authorized to: (check all that apply)  Charge fee(s) indicated below  Credit any overpayments   |   | 2 2,520   | 1812 2.5             |                  | iling a request for ex parte reexamination                              |                       |  |
| Charge any additional fec(s) or any underpayment of fee(s).   |   | 4 920*  | 1604 9               |                  | uesting publication of SIR prior to<br>Miner action                     | <b>└──┤</b> ┃         |  |
| Charge (ee(s) Indicated below, except for the filing fee to the above-identified deposit account.   |   | 5 1,840*  | 1805 1,8             |                  | uesting publication of SIR after<br>miner action                        | <u> </u>              |  |
| FEE CALCULATION   | 125   | 1 110   | 2251                 | 55 Exte          | ension for raply within first month                                     |                       |  |
| 1. BASIC FILING FEE   |   | 2 420   | 1                    |                  | ansion for reply within second month                                    |                       |  |
| Large Entity Small Entity   | 125   |   | 2253 4               | 475 Exte         | ension for raply within third month                                     | 950.00                |  |
| Fee Fee Fee Fee Fee Description Fee Paid Code (\$) Code (\$)  | l   | 4 1,480   | 1                    |                  | ension for reply within fourth month                                    | 950.00                |  |
| 1001 770 2001 385 Utility filing fee  | 125   | 5 2,010   | •                    | ,005 Exte        | ension for repty within fifth month                                     |                       |  |
| 1002 340 2002 170 Design Ming fee   | 140   |   | 1                    |                  | ice of Appeal   |                       |  |
| 1003 530 2003 265 Plant filing fee  | 140   |   | 1                    |                  | ng a brief in support of an appeal                                      |                       |  |
| 1004 770 2004 385 Reisaue filing fee  | 140   |   | I -                  | -                | juest for oral hearing  |                       |  |
| 1005 160 2005 80 Provisional filing fee   | 145   | i 1,510<br>2 110  | 1451 1,<br>2452      |                  | tion to institute a public use proceeding the to revive - unavoidable   |                       |  |
| SUBTOTAL (1) (\$)   |   | 3 1,330   | 1                    |                  | ilion to revive - unintentional   |                       |  |
| 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE   |   | 1 1,330   | 17                   |                  | lty lasue fee (or reissue)  |                       |  |
| Fee from Extra Claims below Fee Paid  | 150   | •   |                      |                  | sign issue fee  |                       |  |
| Total Claims 20** = X =   | 150   | 3 640   |                      |                  | nt issue fee  |                       |  |
| Independent - 3** = X = =   | 146   | 0 130   | 146D                 | 130 Pat          | itions to the Commissioner  |                       |  |
| Multiple Dependent =  | 160   | 7 50  | 1807                 | 50 Pro           | cessing fee under 37 CFR 1.17(q)  |                       |  |
| Large Entity   Small Entity   Fee Fee   Fee Fee Fee Fee Description   | 180   | 6 180   | 1806                 |                  | mission of Information Disclosure Strat                                 |                       |  |
| Fee Fee Fee Fee Fee Pescription Code (\$) Code (\$)   | 802   | 1 40  | 8021                 | 40 Rec           | ording each patent assignment per<br>perty (times number of properties) |                       |  |
| 1202 18 2202 9 Claims in excess of 20   | 180   | 9 770   | 2809                 | 385 Filir        | ng a submission after final rejection                                   |                       |  |
| 1201 86 2201 43 Independent claims in excess of 3 1203 280 2203 145 Multiple dependent claim, if not paid   | 181   | 0 770   | 2810                 | -                | CFR 1.129(a))<br>each additional invention to be                        |                       |  |
| 1204 86 2204 43 ** Reissue independent claims   |   |   | ľ                    | t)XCa            | mined (37 CFR 1.129(b))   |                       |  |
| over original palent  |   | 01 770  | 2801                 |                  | equest for Continued Examination (RCE)                                  | <b></b>               |  |
| 1205 18 2205 9 ** Reisaue claims in excess of 20 and over original patent   | 180   | 2 900   | 1802                 |                  | equest for expedited examination<br>a design application                |                       |  |
| SUBTOTAL (2) (\$)   | Other fee (specify)                                       |   |                      |                  |   |                       |  |
| or number previously paid, if greater, For Reissues, see above  | Reduced by Basic Filing Fee Pald SUBTOTAL (3) (\$) 950.00 |   |                      |                  |   |                       |  |
| SUBMITTED BY (Complete (if applicable))   |   |   |                      |                  |   |                       |  |
| Name (Print/Time)   Elicabeth   assen   Registration No. 31 R45   Telephone 508-270-2553  |   |   |                      |                  |   |                       |  |
| Signature Chaluth Ann Date 3/10/4   |   |   |                      |                  |   | 1                     |  |
| Conditional I Walled All All  |   | _   |                      |                  | 1200  | 7                     |  |

WARNING: Information on this form may become public. Credit card Information should not

be included on this form Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and authoriting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent

Our Docket: GA0150C

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Roberts et al.

Serial No.: 09/826,609

Filed: April 5, 2001

For: GENES DIFFERENTIALLY EXPRESSED IN CANCER CELLS TO DESIGN CANCER VACCINES

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Art Unit: 1642

Examiner: Karen A. Canella

RECEIVED
CENTRAL FAX CENTER

APR 2 2 2004

OFFICIAL

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA VIRGINIA 22313-1450

<u>//www.</u>

Signature of person mailing correspondence

## RESPONSE TO OFFICE ACTION UNDER 37 C.F.R. § 1.111

Sir:

This communication is being filed in response to the non-final Office Action mailed September 10, 2003 in connection with the above-identified application. A response to the non-final Office Action was originally due December 10, 2003. As part of this Communication, Applicant is filing a Petition for a Three Month Extension of Time, thereby extending the deadline to file a response to the September 10, 2003. Office Action to March 10, 2003. Accordingly, this response is timely filed.